KLP Kapitalforvaltning AS Sells 37,900 Shares of United Therapeutics Corporation $UTHR

KLP Kapitalforvaltning AS trimmed its position in United Therapeutics Corporation (NASDAQ:UTHR) by 63.3% during the third quarter, Holdings Channel reports. The institutional investor owned 22,000 shares of the biotechnology company’s stock after selling 37,900 shares during the quarter. KLP Kapitalforvaltning AS’s holdings in United Therapeutics were worth $9,223,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in UTHR. CWM LLC raised its position in shares of United Therapeutics by 204.3% during the 2nd quarter. CWM LLC now owns 5,194 shares of the biotechnology company’s stock valued at $1,492,000 after acquiring an additional 3,487 shares during the last quarter. AXQ Capital LP boosted its position in shares of United Therapeutics by 495.4% in the 2nd quarter. AXQ Capital LP now owns 3,888 shares of the biotechnology company’s stock worth $1,117,000 after purchasing an additional 3,235 shares during the last quarter. Osaic Holdings Inc. grew its stake in shares of United Therapeutics by 271.0% during the second quarter. Osaic Holdings Inc. now owns 46,082 shares of the biotechnology company’s stock worth $14,027,000 after purchasing an additional 33,662 shares during the period. Simplify Asset Management Inc. bought a new stake in United Therapeutics in the third quarter valued at about $8,351,000. Finally, Merit Financial Group LLC lifted its stake in United Therapeutics by 56.3% in the third quarter. Merit Financial Group LLC now owns 7,416 shares of the biotechnology company’s stock valued at $3,109,000 after buying an additional 2,672 shares during the period. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Stock Down 2.6%

United Therapeutics stock opened at $490.83 on Friday. The company has a 50 day moving average of $483.18 and a 200-day moving average of $400.13. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $519.99. The stock has a market capitalization of $21.14 billion, a PE ratio of 18.60, a price-to-earnings-growth ratio of 2.61 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, beating the consensus estimate of $6.89 by $0.27. The business had revenue of $799.50 million for the quarter, compared to analysts’ expectations of $812.87 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The firm’s revenue was up 6.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $6.39 EPS. Equities analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In related news, COO Michael Benkowitz sold 22,500 shares of the stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $427.41, for a total transaction of $9,616,725.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 608,514 shares of company stock worth $284,376,421 over the last ninety days. 10.30% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on UTHR shares. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. Wells Fargo & Company lifted their price objective on shares of United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 30th. Jefferies Financial Group restated a “buy” rating and set a $575.00 price objective on shares of United Therapeutics in a report on Wednesday, November 19th. Morgan Stanley set a $447.00 target price on shares of United Therapeutics in a report on Wednesday, October 29th. Finally, HC Wainwright lifted their price target on shares of United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, United Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $509.50.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.